Albert Fleury

Albert Fleury has held several roles in the healthcare and medical device industry. From 2022 to present, they have been the VP, Cryopreserved Platelets & Capital Support at Cellphire Therapeutics, Inc., where they lead the Cryopreserved Platelet Business Unit and is responsible for management of ongoing multi-year US Army Medical Research Acquisition Activity (USAMRAA) contract, ongoing Phase 2/3 clinical trial in cardiac surgery patients, and CMC/product development activities. From 2014 to present, they have been the President, COO and CFO at Cordex Systems, Inc., where they managed all operational and financial aspects of the early stage healthcare and medical device company. From 2013 to 2014, they were an Associate at Fairfax Partners. From 2007 to 2013, they were the Director - Corporate Finance and Investor Relations; Business Development at QIAGEN. From 2001 to 2007, they were the Investor Relations at Digene Corporation, where they set up the investor relations department and communicated the financial and strategic rationale of the acquisition to investors.

Albert Fleury received their MBA from The Wharton School in 2008, where they studied Finance. Prior to that, they obtained a BS from Duke University in 2001, with a dual major in Economics and Molecular Biology.